Glatiramer acetate or IFN-ß bridging therapy in women with relapsing multiple sclerosis planning a pregnancy.
Neurodegener Dis Manag
; 13(4): 223-234, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37382065
ABSTRACT
Aim:
To assess bridging glatiramer acetate (GA) or IFN-ß for relapse prevention in women with relapsing multiple sclerosis planning pregnancy. Materials &methods:
Participants discontinued disease-modifying therapies (DMTs) and received GA/IFN (early- or delayed-start) or no DMT (control) until pregnancy.Results:
Annualized relapse rate was lower in delayed-start GA/IFN cohort versus control during washout/bridging. During washout/bridging, bridging with GA/IFN in this cohort reduced clinical activity, while disease activity increased in controls versus baseline.Conclusion:
More data on GA/IFN bridging are needed. Women with low relapsing multiple sclerosis activity in the year prior to DMT discontinuation due to pregnancy planning benefited from GA/IFN bridging with lower annualized relapse rate versus no treatment and reduced clinical activity versus baseline during washout/bridging and pregnancy.
When women with relapsing multiple sclerosis (RMS) plan a pregnancy, doctors must think about the possible effects of medicines. Patients can take medicines with a well-defined safety profile to reduce the risk of attacks after stopping strong treatments. In this study, women stopped taking their RMS medicines and either took well-defined RMS medicines, glatiramer acetate (GA) or IFN-ß; or stopped all RMS medicines. The rate of attacks (in a year) was lower in patients who started taking GA/IFN a while after stopping their previous RMS medicines compared with patients who took no more medication. Women with low RMS activity in the year before stopping RMS treatment because of pregnancy planning may benefit from GA/IFN treatment prior to conception.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
Multiple Sclerosis
Limits:
Female
/
Humans
/
Pregnancy
Language:
En
Journal:
Neurodegener Dis Manag
Year:
2023
Document type:
Article
Affiliation country:
Alemania